Last reviewed · How we verify
LipoCol and Mevacor
LipoCol and Mevacor is a HMG-CoA reductase inhibitor (statin) Small molecule drug developed by Taipei Medical University WanFang Hospital. It is currently FDA-approved for Hypercholesterolemia, Primary prevention of coronary heart disease, Secondary prevention of cardiovascular events in patients with established coronary artery disease.
LipoCol and Mevacor are statins that inhibit HMG-CoA reductase to reduce cholesterol synthesis in the liver.
LipoCol and Mevacor are statins that inhibit HMG-CoA reductase to reduce cholesterol synthesis in the liver. Used for Hypercholesterolemia, Primary prevention of coronary heart disease, Secondary prevention of cardiovascular events.
At a glance
| Generic name | LipoCol and Mevacor |
|---|---|
| Sponsor | Taipei Medical University WanFang Hospital |
| Drug class | HMG-CoA reductase inhibitor (statin) |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Both drugs block the enzyme HMG-CoA reductase, which catalyzes an early and rate-limiting step in cholesterol biosynthesis. By reducing hepatic cholesterol production, they lower LDL cholesterol levels in the blood and reduce cardiovascular risk. Mevacor (lovastatin) is a naturally derived statin, while LipoCol typically refers to a lovastatin-based formulation.
Approved indications
- Hypercholesterolemia
- Primary prevention of coronary heart disease
- Secondary prevention of cardiovascular events in patients with established coronary artery disease
Common side effects
- Myalgia (muscle pain)
- Elevated liver enzymes
- Rhabdomyolysis
- Headache
- Gastrointestinal upset
Key clinical trials
- Pharmacokinetic and Drug Interaction Study of Red Yeast Rice Capsules (PHASE4)
- Lovastatin and Its ß-hydroxy Acid From Four 600 mg LipoCol Forte® Capsules Compared to That of One 20 mg Mevacor® Tablet in Healthy Subjects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LipoCol and Mevacor CI brief — competitive landscape report
- LipoCol and Mevacor updates RSS · CI watch RSS
- Taipei Medical University WanFang Hospital portfolio CI
Frequently asked questions about LipoCol and Mevacor
What is LipoCol and Mevacor?
How does LipoCol and Mevacor work?
What is LipoCol and Mevacor used for?
Who makes LipoCol and Mevacor?
What drug class is LipoCol and Mevacor in?
What development phase is LipoCol and Mevacor in?
What are the side effects of LipoCol and Mevacor?
What does LipoCol and Mevacor target?
Related
- Drug class: All HMG-CoA reductase inhibitor (statin) drugs
- Target: All drugs targeting HMG-CoA reductase
- Manufacturer: Taipei Medical University WanFang Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypercholesterolemia
- Indication: Drugs for Primary prevention of coronary heart disease
- Indication: Drugs for Secondary prevention of cardiovascular events in patients with established coronary artery disease
- Compare: LipoCol and Mevacor vs similar drugs
- Pricing: LipoCol and Mevacor cost, discount & access